BioCentury
ARTICLE | Company News

Takeda, AstraZeneca deal

December 21, 2015 8:00 AM UTC

AstraZeneca will acquire Takeda’s core respiratory business, including Daliresp roflumilast, Alvesco ciclesonide, Omnaris ciclesonide nasal spray and seven undisclosed early pipeline products. Takeda will receive a $575 million upfront payment and will transfer about 200 staff to AZ. The deal is slated to close next quarter. ...